Dr Reddy's Laboratories Ltd (RDY) (HY 2025) Earnings Call Highlights: Strong Revenue Growth and ... [Yahoo! Finance]
Dr. Reddy's Laboratories Ltd (RDY)
US:NYSE Investor Relations:
drreddys.com/investors
Company Research
Source: Yahoo! Finance
Gross Profit Margin: 59.6%, increased by 92 basis points YoY, decreased by 81 basis points sequentially. SG&A Expenses: INR2,301 crore (USD275 million), 22% YoY increase, 1% sequential increase. R&D Spend: INR727 crore (USD87 million), 33% YoY increase, 17% sequential increase, 9.1% of sales. EBITDA: INR2,280 crore (USD272 million), 5% YoY increase, 6% sequential increase, EBITDA margin at 28.4%. Profit Before Tax (PBT): INR1,917 crore (USD229 million), PBT margin at 23.9%. Profit After Tax (PAT): INR1,342 crore (USD160 million), PAT margin at 16.7% of revenues. Free Cash Flow: INR204 crore (USD24 million). Net Cash Surplus: INR1,889 crore (USD226 million) as of September 30, 2024. North America Generic Revenue: USD445 million, 16% YoY growth, 4% sequential decline. European Generic Revenue: EUR63 million, 7% YoY and sequential growth. Emerging Markets Generic Revenue: INR1,455 crore, 20% YoY growth, 23% sequential growth. India Business Revenue: INR1,397 crore,
Show less
Read more
Impact Snapshot
Event Time:
RDY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RDY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RDY alerts
High impacting Dr. Reddy's Laboratories Ltd news events
Weekly update
A roundup of the hottest topics
RDY
News
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.MarketBeat
- Pulmonary Arterial Hypertension Drugs Market to Grow by USD 2.26 Billion from 2024-2028, as Rising PAH Prevalence Drives Demand with AI Redefining Market Landscape - Technavio [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Q2 Earnings Miss Estimates, Global Generics Revenues Grow [Yahoo! Finance]Yahoo! Finance
- Dr. Reddy's Laboratories Limited (NYSE: RDY) had its price target lowered by analysts at Barclays PLC from $17.40 to $17.00. They now have an "overweight" rating on the stock.MarketBeat
- Dr. Reddy's Laboratories Limited (NYSE: RDY) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.MarketBeat
RDY
Earnings
- 11/6/24 - Beat
RDY
Sec Filings
- 11/14/24 - Form 6-K
- 11/12/24 - Form 6-K
- 11/7/24 - Form 6-K
- RDY's page on the SEC website